ASML Holding N.V. (ASML)
Verdict history · ASML
Every call Verdix has made on ASML.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
The prior WAIT verdict at $1,844 reflected a panel that included The Disruptive-Innovation Seeker and The Forensic Skeptic — two voices that framed the risk around technology disruption and accounting scrutiny. Since then, the stock pulled back 4.4% to $1,764, and the reconstituted panel swaps in The Asymmetric Bargainer and The Macro Opportunist, both of whom land on the same conclusion through different frameworks: the business case is near-unanimous, but the price case still offers no edge. The shift from WAIT to BALANCED reflects not a change in business quality but a recognition that even at a slightly lower price, the asymmetry has not opened up enough to justify committing new capital.
See methodology for how verdicts are produced. Full track record →
The panel’s split verdict on ASML — and where they disagree.
The case for and against roughly balance — no clear edge at today's price.
NASDAQ · Information Technology / Semiconductor Equipment · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BalancedMEDIUM confidence
Why
ASML's EUV monopoly and AI-driven order book earn near-unanimous respect from the panel, but at 56x trailing earnings and with the first weekly MACD bearish cross of the rally, the price divides the room evenly — three voices see a durable compounder worth holding and three see compressed asymmetry that offers no edge for new capital.Level to watch
Key resistance 1,850+4.9% from 1,763.76
Next catalyst
Pullback to the accumulation zone: A move into $1,419 to $1,509 with the weekly MACD histogram beginning to curl upward would flip the panel to BUY by restoring a margin of safety beneath the intrinsic-value range.The panel's take
Verdict: BALANCED · Conviction: MEDIUM · Last price: 1763.76 · Changed from WAIT
Panel: 3 Bullish · 2 Neutral · 1 Bearish → BALANCED
What changed since 2026-08-15:
- Price: 1844.08 → 1763.76 (-4.36%)
- Panel: 2 of 6 → 3 of 6 now Bullish — composition also changed: added The Asymmetric Bargainer, The Macro Opportunist; removed The Disruptive-Innovation Seeker, The Forensic Skeptic
- Trigger: A pullback into the $1,419–1,509 zone with the weekly MACD histogram starting to curl up flips BALANCED to BUY. A weekly close above $1,850 that invalidates the bearish MACD cross also flips to BUY. A weekly close below the EMA50 at $1,419 breaks the Stage 2 structure and flips to SELL.
- Verdict: WAIT → BALANCED
The prior WAIT verdict at $1,844 reflected a panel that included The Disruptive-Innovation Seeker and The Forensic Skeptic — two voices that framed the risk around technology disruption and accounting scrutiny. Since then, the stock pulled back 4.4% to $1,764, and the reconstituted panel swaps in The Asymmetric Bargainer and The Macro Opportunist, both of whom land on the same conclusion through different frameworks: the business case is near-unanimous, but the price case still offers no edge. The shift from WAIT to BALANCED reflects not a change in business quality but a recognition that even at a slightly lower price, the asymmetry has not opened up enough to justify committing new capital.
Three of six see a durable moat worth owning, but even the bulls concede the price is full — The Quality Rationalist would not buy at $1,763.76 — and the remaining three cite compressed asymmetry at 56x trailing P/E and a weekly MACD bearish cross, the first technical warning since the rally began. The business case is near-unanimous; the price case divides the panel evenly, leaving no edge for new money.
Key levels
Key levels · ASML
USD · as of 2026-08-22Analyst consensus target 2,195.39 USD · range 895.31–2,873.89
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key support at $1,661 is the weekly EMA20 — the first line of defense, ~6% below price and the level the technical scout flagged as the gatekeeper for the Stage 2 thesis. At $1,509 the weekly Fib 38.2% retracement of the $716–$1,999.96 rally marks the upper bound of the zone where The Macro Opportunist, The Quality Rationalist, and The GARP Operator all say they would buy; the weekly EMA50 at $1,419 is the structural floor — a break below it ends the Stage 2 uptrend entirely. Key resistance at $1,850 is the level Macro Opportunist says would invalidate the weekly MACD bearish cross and confirm a bullish re-acceleration; the all-time high at $1,999.96 is the ultimate ceiling. The analyst consensus target of $2,195 sits 24.5% above the current price.
What legendary investors think
We ran ASML Holding N.V. past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: At a PEG ratio of 1.09 on 55% forecast EPS growth, 30% net margins, and a net-cash balance sheet, ASML checks every GARP box except the entry price, where the weekly pullback toward $1,661 is normal digestion in a 146% rally. Conviction: Conviction is held in check by the trailing P/E of 56x, which means any growth deceleration would compress the multiple before the PEG math can play out.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralLow
Signal: Revenue growth of 30% in FY2026 and 32% target margins produce a base-case intrinsic value of $1,600, roughly 9% below the current price, leaving no margin of safety for a stock priced to perfection with 0.3% short interest. Conviction: The missing ROIC figure prevents anchoring the reinvestment rate, so the terminal value — where most of the valuation lives — rests on assumptions I cannot verify.
The Scuttlebutt Growth InvestorGrowth/Management🟢 BullishMed
Signal: The CEO's explicit commitment to 30% annual capacity expansion across two years and a raised FY2026 revenue guide confirm that customer demand is accelerating, not merely sustaining, the near-monopoly in EUV lithography. Conviction: Three checklist items — labor relations, executive relations, and equity dilution — remain unverified, and those gaps matter more when paying 56x trailing earnings.
The Quality RationalistMental Models/Quality🟢 BullishMed
Signal: A near-monopoly producing 54% ROE, 30% net margins, and a net-cash balance sheet is the definition of a wonderful business, but at 56x trailing earnings with 83% of analysts at Buy, the price reflects near-unanimous optimism and leaves no room for error. Conviction: The first weekly MACD bearish cross since the rally began reinforces what the multiple already signals: patience for a pullback into the $1,400 to $1,500 zone is the rational posture, not a bet against the business.
The Asymmetric BargainerContrarian/Deep Value🔴 BearishMed
Signal: With 56x trailing earnings, 0.3% short interest, and 83% analyst Buy ratings, the stock prices in flawless execution, failing the Dhandho test that requires limited downside relative to the upside. Conviction: The expected value tilts negative because the 40% probability of a 35% drawdown outweighs the 15% probability of a 50% gain, a payoff structure that offers no edge for a new position.
The Macro OpportunistMacro/Timing⚫ NeutralMed
Signal: The first weekly MACD bearish cross of the entire rally arrives while forward P/E sits at 33x, and with an upside-to-downside ratio of 0.55:1 at the current price, the market is not compensating new entrants for sitting through the next drawdown. Conviction: The secular AI buildout thesis remains intact — management raised guidance 20% at the midpoint — but respecting the first technical damage signal after a 146% run is how you avoid owning the best story at the worst price.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- ASML holds a near-monopoly in EUV lithography that faces no credible competitive threat within the next 5 to 10 years.
- The AI-driven demand cycle is genuine, substantiated by raised FY2026 guidance and a 30% capacity expansion plan backed by real capital commitments.
- The balance sheet is exceptional: net cash, minimal debt (D/E 9.1%), 30%+ net margins, and 54% ROE.
- At roughly $1,764, the current price offers no margin of safety for new money — every voice on the panel, bull or bear, concedes the price is full.
The real debate
- The GARP Operator sees a PEG of 1.09 as a fair entry for a fast-grower with accelerating earnings, while The Asymmetric Bargainer sees 56x trailing earnings as a Dhandho non-starter where a 35% drawdown is more probable than a 50% gain.
- The Scuttlebutt Growth Investor treats the CEO's capacity expansion commitment and raised guidance as confirming the growth runway is intact and investable; The Macro Opportunist treats the weekly MACD bearish cross as confirming the entry timing is wrong regardless of how strong the growth story is.
- The Quality Rationalist judges the business wonderful but refuses to buy at $1,764, while The Intrinsic-Value Modeler's base case of $1,600 implies the stock is modestly overvalued, not merely poorly timed — a subtle but real split between those who would buy lower and those who think even intrinsic value sits below the current quote.
The question it comes down to: Is ASML's EUV monopoly and AI-driven order acceleration worth paying 56x trailing earnings for, or does the first weekly MACD bearish cross of the rally confirm that the price has run ahead of even the best-case growth trajectory?
The bottom line
- Pullback to the accumulation zone: A move into $1,419 to $1,509 with the weekly MACD histogram beginning to curl upward would flip the panel to BUY by restoring a margin of safety beneath the intrinsic-value range.
- Breakout to confirm momentum reset: A weekly close above $1,850 that invalidates the bearish MACD cross would signal the technical damage is repaired and flip the verdict to BUY.
- Support that must hold: A weekly close below the EMA50 at $1,419 would break the Stage 2 monthly structure and flip the verdict to SELL.
- Next catalyst: The October Q3 2026 earnings print will test whether the raised guidance holds; any softening in order-intake language would erode the growth foundation that every bull on the panel relies on.
- Geopolitical risk to monitor: Any escalation of US or Dutch export controls that materially cuts China revenue would force a re-rating across the entire panel.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in ASML · ASML verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated